US Edition
Published • loading... • Updated
NHS spending watchdog to review evidence on Alzheimer’s treatments
Summary by ethicalmarketingnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
NHS spending watchdog to review evidence on Alzheimer’s treatments
England’s drugs costs watchdog is to look again at whether new treatments for Alzheimer’s disease should be made available on the NHS. An appeal found that National Institute for Health and Care Excellence (NICE) had failed to properly account for the wider impact of the treatments, including the heavy burden on unpaid carers, when calculating the cost effectiveness of the medicines. Both treatments, lecanemab and donanemab, will now return to a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
